PGD2 for Bleomycin B2

Phase-Based Progress Estimates
Bleomycin B2
PGD2 - Other
All Sexes
What conditions do you have?

Study Summary

This study is evaluating whether there is a previously unrecognized metabolic pathway between two prostaglandins.

Treatment Effectiveness

Study Objectives

1 Primary · 0 Secondary · Reporting Duration: 0-10 hours

0-10 hours
prostaglandin metabolites

Trial Safety

Trial Design

4 Treatment Groups

deuterated PGD2
1 of 4
niacin + low-dose aspirin
1 of 4
1 of 4
niacin + regular-strength aspirin
1 of 4
Experimental Treatment

10 Total Participants · 4 Treatment Groups

Primary Treatment: PGD2 · No Placebo Group · Phase < 1

deuterated PGD2
Experimental Group · 1 Intervention: PGD2 · Intervention Types: Other
niacin + low-dose aspirinExperimental Group · 2 Interventions: niacin, aspirin · Intervention Types: DietarySupplement, Drug
Experimental Group · 1 Intervention: niacin · Intervention Types: DietarySupplement
niacin + regular-strength aspirinExperimental Group · 2 Interventions: niacin, aspirin · Intervention Types: DietarySupplement, Drug
First Studied
Drug Approval Stage
How many patients have taken this drug
Completed Phase 4
Acetylsalicylic acid
FDA approved

Trial Logistics

Trial Timeline

Approximate Timeline
Screening: ~3 weeks
Treatment: Varies
Reporting: 0-10 hours

Who is running the clinical trial?

Vanderbilt University Medical CenterOTHER
768 Previous Clinical Trials
592,104 Total Patients Enrolled
Vanderbilt UniversityLead Sponsor
682 Previous Clinical Trials
6,131,386 Total Patients Enrolled
Claus M Schneider, PhDPrincipal InvestigatorVanderbilt University

Eligibility Criteria

Age 18+ · All Participants · 1 Total Inclusion Criteria

Mark “yes” if the following statements are true for you:

About The Reviewer

Michael Gill preview

Michael Gill - B. Sc.

First Published: October 24th, 2021

Last Reviewed: October 28th, 2022

Michael Gill holds a Bachelors of Science in Integrated Science and Mathematics from McMaster University. During his degree he devoted considerable time modeling the pharmacodynamics of promising drug candidates. Since then, he has leveraged this knowledge of the investigational new drug ecosystem to help his father navigate clinical trials for multiple myeloma, an experience which prompted him to co-found Power Life Sciences: a company that helps patients access randomized controlled trials.